CTI BioPharma Corp. (CTIC) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, CTIC's 50-day simple moving average crossed above ...
The market expects CTI BioPharma (CTIC) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2023. This widely-known consensus ...
CTI BioPharma (NASDAQ:CTIC) stock is taking off on Wednesday after the company announced a major acquisition deal with Sobi. This deal has Sobi agreeing to acquire CTI BioPharma for $1.7 billion. This ...
DYNAMIC PAGE -- HIGHEST POSSIBLE CLASSIFICATION IS TOP SECRET // SI / TK // REL TO USA AUS CAN GBR NZL (U//FOUO) CTIC: It's Not Just Another Pretty Space FROM: the Counterterrorism Primary Production ...
as a treatment for myelofibrosis patients with severe thrombocytopenia. The company notes that this comes after a successful pre-NDA meeting with the U.S. Food and Drug Administration (FDA). CTI ...
Dividend history information is presently unavailable for this company. This could indicate that the company has never provided a dividend or that a dividend is pending. Nasdaq Data provided by Nasdaq ...
A new defensive cyberspace operations facility at Joint Base San Antonio will boost the 35th Intelligence Squadron’s ability to meet growing demands for analysis of intelligence coming from multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results